506 Durable disease stabilization and antitumor activity with rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, in combination with gemcitabine: a phase I and pharmacokinetic study in patients with advanced cancer

Authors :: Emiliano Calvo
Anthony W. Tolcher
K. L. Mettinger
Amita Patnaik
Andrew Goetz
Alain C. Mita
M. Knepper
Quincy Chu
E.K. Rowinksy
Muralidhar Beeram
Source :: European Journal of Cancer Supplements. 2:154-155
Publication Year :: 2004
Publisher :: Elsevier BV, 2004.

Subjects :: Antitumor activity
Cancer Research
biology
business.industry
Topoisomerase
Disease
Pharmacology
Advanced cancer
Gemcitabine
Oncology
Pharmacokinetics
Rubitecan
biology.protein
Medicine
In patient
business
medicine.drug

Tools